<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633813</url>
  </required_header>
  <id_info>
    <org_study_id>CD-13-661</org_study_id>
    <nct_id>NCT02633813</nct_id>
  </id_info>
  <brief_title>BE Study of Naftifine HCL</brief_title>
  <official_title>A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzum Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genzum Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study was randomized, double blind, placebo-controlled, prospective, multicenter,
      comparative therapeutic equivalence study.

      The study duration for each patient was 6 weeks: Following were the visit details.

      V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 +
      2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at
      the end of week 6 + 4 days).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mycological cure and clinical cure for a single target lesion for Trichyphyton rubrum</measure>
    <time_frame>week 6 + 4 days</time_frame>
    <description>After 6 weeks the skin scrapping will be collected for culture to find out the growth of T rubrum. Absence of growth suggests complete cure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycological cure and clinical cure for Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum</measure>
    <time_frame>week 6 + 4 days</time_frame>
    <description>After 6 weeks the skin scrapping will be collected for culture to find out the growth of T rubrum, T Mentagrophytes or E floccosum. Absence of growth suggests complete cure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of AEs for each treatment groups</measure>
    <time_frame>week 6 + 4 days</time_frame>
    <description>number of adverse events reported will be collated from all the treatment arms, to evaluate the safety of the study drugs.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">693</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Naftifine hydrochloride 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftin® 2% (Naftifine hydrochloride 2%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vehicle cream.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftifine hydrochloride 2%</intervention_name>
    <description>Topical application for two weeks</description>
    <arm_group_label>Naftifine hydrochloride 2%</arm_group_label>
    <other_name>Naftifine hcl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical application for two weeks</description>
    <arm_group_label>Placebo vehicle cream.</arm_group_label>
    <other_name>Vehicle cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin® 2% (Naftifine hydrochloride 2%)</intervention_name>
    <description>Topical application for two weeks</description>
    <arm_group_label>Naftin® 2% (Naftifine hydrochloride 2%)</arm_group_label>
    <other_name>Naftifine hcl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females aged more than or equal to 18 years

          2. Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or
             predominantly interdigital, but may extend to other areas of the foot (the
             non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea
             pedis moccasin), and provisionally confirmed at baseline by a positive potassium
             hydroxide (KOH) wet mount preparation (i.e., skin scrapings from the target site are
             placed on a microscope slide with a drop of 10% KOH, and microscopic examination
             reveals segmented fungal hyphae)

          3. The sum of the clinical signs and symptoms scores of the target lesion is at least 4,
             including a minimum score of at least 2 for erythema AND a minimum score of 2 for
             either scaling or pruritus (on a scale of 0-3, where 2 indicates moderate severity)

        Exclusion Criteria:

          1. Pregnant or lactating or planning to become pregnant during the study period

          2. Use of antipruritics, including antihistamines, within 72 hours prior to entry into
             the study

          3. Use of topical corticosteroid, antibiotics or antifungal therapy within 2 weeks prior
             to entry into the study

          4. Use of systemic (e.g., oral or injectable) corticosteroid, antibiotics or antifungal
             therapy within 1 month prior to entry into the study

          5. Use of oral terbinafine or itraconazole within 2 months prior to entry into the study

          6. Use of immunosuppressive medication or radiation therapy within 3 months prior to
             entry into the study.

          7. Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.

          8. Presence of any other infection of the foot or other disease process that might
             confound the treatment evaluation

          9. History of dermatophyte infections unresponsive to systemic or topical antifungal
             drugs

         10. Known hypersensitivity to Naftifine Hydrochloride or to any component of the
             formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaidoon Al-Zubaidy</last_name>
    <role>Study Chair</role>
    <affiliation>Catawba Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moore Clinical Research Inc</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Savin Medical Group Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc,</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Miramar</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Tampa, MOORE Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tampa MOORE Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi Search</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practise</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dermatológico y Cirugía de Piel</name>
      <address>
        <city>Santo Domingo</city>
        <state>San Cristóbal</state>
        <zip>91000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dermatológico</name>
      <address>
        <city>Barrio Maria Auxiliadora</city>
        <state>Santo Domingo</state>
        <zip>10305</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Tinea pedis</keyword>
  <keyword>Naftin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naftifine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

